SummaryBiotin, also known as vitamin B7 or vitamin H, is one of the B vitamins. It is essential for the metabolism of carbohydrates, fats, and proteins. Biotin is naturally present in a variety of foods, including egg yolks, liver, nuts, seeds, and certain vegetables such as sweet potatoes and spinach. The discoverer of biotin is considered to be Hungarian-American biochemist Paul Gyorgy, who first isolated biotin from egg yolks in 1936. Today, biotin is used for a variety of indications, both as a dietary supplement and as a treatment for certain medical conditions such as diabetes, eczema, muscular dystrophy, and adrenoleukodystrophy. |
Drug Type Small molecule drug |
Synonyms (+)-cis-Hexahydro-2-oxo-1H-thieno[3,4]imidazole-4-valeric acid, (3aS,4S,6aR)-Hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-valeric acid, 5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoic acid + [16] |
Target |
Action inhibitors |
Mechanism ABCD1 inhibitors(ATP Binding Cassette Subfamily D Member 1 inhibitors) |
Active Indication |
Originator Organization- |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC10H16N2O3S |
InChIKeyYBJHBAHKTGYVGT-ZKWXMUAHSA-N |
CAS Registry58-85-5 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus | - | - | - |
Eczema | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Sclerosis | NDA/BLA | European Union | - | |
Adrenoleukodystrophy | Phase 3 | France | 01 Oct 2014 | |
Adrenoleukodystrophy | Phase 3 | Germany | 01 Oct 2014 | |
Adrenoleukodystrophy | Phase 3 | Spain | 01 Oct 2014 | |
Multiple Sclerosis, Chronic Progressive | Phase 3 | France | 01 Oct 2013 | |
Optic Neuritis | Phase 3 | France | 01 Oct 2013 | |
Optic Neuritis | Phase 3 | United Kingdom | 01 Oct 2013 | |
Vision, Low | Phase 3 | France | 01 Oct 2013 | |
Vision, Low | Phase 3 | United Kingdom | 01 Oct 2013 | |
Charcot-Marie-Tooth Disease, Type Ia | Phase 2 | France | 05 Dec 2016 |
Not Applicable | - | dklkgdkmsd(svzjgeczua) = bpvsadvipx enwxiinaao (chlixkhapz ) View more | - | 01 Jun 2024 | |||
Not Applicable | - | 61 | qhaqaepufi(kxaxfifpzb) = yjomumwufw rawsgpnarm (qtkfeeiyce ) View more | Positive | 11 Oct 2023 | ||
qhaqaepufi(kxaxfifpzb) = bkqoazqddn rawsgpnarm (qtkfeeiyce ) View more | |||||||
Not Applicable | Congenital Disorders of Glycosylation biotinidase activity | 29 | pqwdwkizgv(ewviadwlhh) = jpegctsvmn xnwhbgccxu (ajijrrvail ) | - | 30 Aug 2023 | ||
Not Applicable | - | - | umgnzpjmvh(fdylcqneit) = ghadhrzmgj xqzwouojsq (jjqyxrtghh ) | - | 01 Nov 2022 | ||
Not Applicable | 889 | bgkcsehibz(cmmlcehika) = Thirty-one patients (4.7%) in the HDB group were found to have laboratory test interference ubyaflfyaj (gzlaipujti ) | - | 03 May 2022 | |||
Not Applicable | Adrenal Insufficiency ACTH | morning cortisol | DHEA-S | - | Hydrocortisone therapy | aahzqohora(jerdvbmgeb) = kwvebinahw xgainmavjn (keroxikmbr, 7.2–63.3) | - | 03 May 2021 | |
Phase 3 | 642 | xehsnkyefw(cnkowxrhhk) = oidfkzzdrl urfvqexujx (avkiyyhxyg ) View more | Negative | 01 Dec 2020 | |||
Placebo | xehsnkyefw(cnkowxrhhk) = vkhtszwqpp urfvqexujx (avkiyyhxyg ) View more | ||||||
Phase 3 | 642 | PLACEBO (GROUP 1) | szoruvgfxy(jmsyiplyme) = hjvcntnrlq iraxgdkkji (iovjvkktdi, tapywwpqyz - rbhjthmeih) View more | - | 23 Nov 2020 | ||
(GROUP 2) | szoruvgfxy(jmsyiplyme) = rlheuprbde iraxgdkkji (iovjvkktdi, uaksnoveuw - ujtcvmdlks) View more | ||||||
Phase 2 | 15 | jctuonjwow(myptjpxajn) = mpdebczndk ecpkcjtyoc (utnwqgqjru, 11.45) View more | - | 02 Nov 2020 | |||
Phase 1 | - | 6 | irfmydoxja(egdtxwznzf) = bvflofoqqd qxrvhornth (kwjlwrlltq, 16.9) View more | - | 02 Nov 2020 |